Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

Journal of Clinical Oncology

Volumn 21, Issue 21, 2003, Pages 3940-3947

  Weng, Wen Kai ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; HISTIDINE; RITUXIMAB; VALINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; FOLLICULAR LYMPHOMA; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; DISEASE FREE SURVIVAL; FEMALE; GENETICS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; STATISTICAL MODEL;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LOGISTIC MODELS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTORS, IGG; TREATMENT OUTCOME;

EID: 0642373290     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.05.013     Document Type: Article

References (31)

1. Shan D, Ledbetter JA, Press OW: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48:673-683, 2000
2. Hofmeister JK, Cooney D, Coggeshall KM: Clustered CD20 induced apoptosis: src-family kinase, proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 26:133-143, 2002
3. Byrd JC, Kitada S, Flinn IW, et al: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood 99:1038-1043, 2002
4. Anderson DR, Grillo-Lopez A, Varns C, et al: Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8), in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 25:705-708, 1997
5. Golay J, Zaffaroni L, Vaccari T, et al: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900-3908, 2000
6. Clynes RA, Towers TL, Presta LG, et al: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446, 2000
7. Weng W-K, Levy R: Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98:1352-1357, 2001
8. Manches O, Lui G, Chaperot L, et al: In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101:949-954, 2003
9. Gaetano ND, Cittera E, Nota R, et al: Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171:1581-1587, 2003
10. Fanger MW, Shen L, Graziano RF, et al: Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today 10:92-99, 1989
11. Cartron G, Dacheux L, Salles G, et al: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc-gamma-R IIIa gene. Blood 99:754-758, 2002
12. Wu J, Edberg JC, Redecha PB, et al: A novel polymorphism of Fc-gamma-RIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 100:1059-1070, 1997
13. Shields RL, Namenuk AK, Hong K, et al: High resolulion mapping of lhe binding site on human IgG1 for Fc-gamma-RI, Fc-gamma-RII, Fc-gamma-RIII, and FcRn and design of IgG1 variants with improved binding lo the Fc-gamma-R. J Biol Chem 276:6591-6604, 2001
14. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 17:1244-1253, 1999
15. Kopreski MS, Benko FA, Kwee C, et al: Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer 76:1293-1299, 1997
16. Koene HR, Kleijer M, Algra J, et al: Fc-gamma-RIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc-gamma-RIIIa, independently of the Fc-gamma-RIIIa-48 L/R/H phenotype. Blood 90:1109-1114, 1997
17. 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). J Immunol Methods 199:55-59, 1996
18. Graziano RF, Ranger MW: Fc-gamma-RI and Fc-gamma-RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells. J Immunol 139:3536-3541, 1987
19. Vance BA, Huizinga TWJ, Wardwell K, et al: Binding of monomeric human IgG defines an expression polymorphism of Fc-gamma-RIII on large granular lymphocyte/natural killer cells. J Immunol 151:6429-6439, 1993
20. Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as first-line therapy of follicular lymphoma patients with low tumor burden: Clinical and molecular evaluation. Blood 97:101-106, 2001
21. Hainsworth JD, Litchy S, Burris HA III, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20:4261-4267, 2002
22. Parren PW, Warmerdam PA, Boeije LC, et al: On the interaction of IgG subclasses with the low affinity Fc-gamma-RIIa (CD32) on human monocytes, neutrophils, and platelets: Analysis of a functional polymorphism to human IgG2. J Clin Invest 90:1537-1546, 1992
23. Lehrnbecher T, Foster CB, Zhu S, et al: Variant genotypes of the low-affinity Fc-gamma receptor in two control populations and a review of low-affinity Fc-gamma receptor polymorphisms in control and disease populations. Blood 94:4220-4232, 1999
24. Kyogoku C, Dijstelbloem HM, Tsuchiya N, et al: Fc-gamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus. Arthritis Rheum 46:1242-1254, 2002
25. Amigorena S, Bonnerot C: Fc receptors for IgG and antigen presentation on MHC class I and class II molecules. Semin Immunol 11:385-390, 1999
26. Kalergis AM, Ravetch JV: Inducing tumor immunity through the selective engagement of activating Fc-gamma receptors on dendritic cells. J Exp Med 195:1653-1659, 2002
27. Regnault A, Lankar D, Lacabanne V, et al: Fc-gamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189:371-380, 1999
28. Ragiq K, Bergtold A, Clynes R: Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 110:71-79, 2002
29. Dhodapkar MV, Krasovsky J, Olson K: T cells from the tumor microenvironment of patients with progressive myeloma can generate strong tumor-specific cytotoxic responses to autologous, tumor-loaded dendritic cells. Proc Nail Acad Sci U S A 99:13009-13013, 2002
30. Dhodapkar KM, Krasovsky J, Williamson B, et al: Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195:125-133, 2002
31. Selenko N, Maidic O, Draxier S, et al: CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 15:1619-1626, 2001